Hisanori Muto

Nagoya, 4548509, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

Journal: Cancers

Published: May 21, 2026

Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis.

Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis.

Journal: Oncology

Published: January 21, 2026

Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab.

Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab.

Journal: Anticancer research

Published: December 16, 2025

The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma.

The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma.

Journal: Biomedicines

Published: December 14, 2025

Biomarker-Based Responder Selection and Early Prediction of Treatment Response in Hepatocellular Carcinoma: Dynamic Changes in Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin During Atezolizumab Plus Bevacizumab Therapy.

Biomarker-Based Responder Selection and Early Prediction of Treatment Response in Hepatocellular Carcinoma: Dynamic Changes in Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin During Atezolizumab Plus Bevacizumab Therapy.

Journal: Cancers

Published: October 26, 2025

Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study.

Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 01, 2025

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma.

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 21, 2025

Soluble Siglec-9 Improves Intestinal Barrier Function in a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis.

Soluble Siglec-9 Improves Intestinal Barrier Function in a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Metabolites

Published: April 13, 2025

Alcoholic Hepatitis in a Japanese Hospital: Losing Contact With Some Patients After Delirium Tremens May Lead to Missed Critical Events.

Alcoholic Hepatitis in a Japanese Hospital: Losing Contact With Some Patients After Delirium Tremens May Lead to Missed Critical Events.

Journal: Addiction biology

Published: November 05, 2024

Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.

Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.

Journal: Current oncology (Toronto, Ont.)

Published: September 01, 2024

Identification of Two Long Noncoding RNAs, Kcnq1ot1 and Rmst, as Biomarkers in Chronic Liver Diseases in Mice.

Identification of Two Long Noncoding RNAs, Kcnq1ot1 and Rmst, as Biomarkers in Chronic Liver Diseases in Mice.

Journal: International journal of molecular sciences

Published: July 21, 2024

Gut microbes associated with functional cure of chronic hepatitis B.

Gut microbes associated with functional cure of chronic hepatitis B.

Journal: Hepatology international

Published: July 20, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026